← All sarcoma trials
Recruiting nowPhase 2Ages 12 Years and up

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Sponsor: Merck Sharp & Dohme LLC · NCT04924075 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorHIF-2α Mutated Cancers

What it tests

  • Belzutifandrug

Where it's running84 sites

  • Cedars-Sinai Medical Center ( Site 0110)

    Los Angeles, California 90048

    Recruiting now

  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130)

    Chicago, Illinois 60611

    Recruiting now

  • Northwestern Medicine Cancer Center - Warrenville ( Site 0134)

    Warrenville, Illinois 60555

    Recruiting now

  • University of Iowa ( Site 0104)

    Iowa City, Iowa 52242

    Recruiting now

  • Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108)

    Baltimore, Maryland 21287

    Recruiting now

  • National Institutes of Health ( Site 0125)

    Bethesda, Maryland 20892

    Recruiting now

  • Massachusetts General Hospital ( Site 0111)

    Boston, Massachusetts 02114

    Recruiting now

  • University of Michigan ( Site 0126)

    Ann Arbor, Michigan 48109

    Recruiting now

  • Washington University-Internal Medicine/Oncology ( Site 0124)

    St Louis, Missouri 63110

    Active, not recruiting

  • Icahn School of Medicine at Mount Sinai ( Site 0123)

    New York, New York 10029

    Active, not recruiting

  • Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127)

    Philadelphia, Pennsylvania 19104

    Active, not recruiting

  • SCRI Oncology Partners ( Site 7000)

    Nashville, Tennessee 37203

    Recruiting now

  • Vanderbilt University Medical Center ( Site 0107)

    Nashville, Tennessee 37232

    Recruiting now

  • University of Texas MD Anderson Cancer Center ( Site 0112)

    Houston, Texas 77030

    Recruiting now
70 international sites

  • Prince of Wales Hospital-Medical Oncology ( Site 1601)

    Randwick, New South Wales, Australia 2031

    Recruiting now

  • The Royal Melbourne Hospital ( Site 1602)

    Parkville, Victoria, Australia 3050

    Recruiting now

  • Arthur J.E. Child Comprehensive Cancer Centre ( Site 0203)

    Calgary, Alberta, Canada T2N 5G2

    Recruiting now

  • Princess Margaret Cancer Centre ( Site 0202)

    Toronto, Ontario, Canada M5G 2M9

    Recruiting now

  • FALP ( Site 2200)

    Santiago, Region M. de Santiago, Chile 7500921

    Recruiting now

  • Centro de Oncología de Precisión ( Site 2203)

    Santiago, Region M. de Santiago, Chile 7560908

    Recruiting now

  • Peking University First Hospital-Urology ( Site 1900)

    Beijing, Beijing Municipality, China 100034

    Active, not recruiting

  • Sun Yat-sen University Cancer Center ( Site 1905)

    Guangzhou, Guangdong, China 510060

    Active, not recruiting

  • Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1904)

    Shanghai, Shanghai Municipality, China 200001

    Active, not recruiting

  • West China Hospital of Sichuan University ( Site 1906)

    Chengdu, Sichuan, China 610041

    Completed

  • Rigshospitalet ( Site 0304)

    Copenhagen, Capital Region, Denmark 2100

    Recruiting now

  • Rigshospitalet-Department of Endocrinology ( Site 0303)

    Copenhagen, Capital Region, Denmark 2100

    Recruiting now

  • Odense Universitetshospital ( Site 0302)

    Odense, Region Syddanmark, Denmark 5000

    Recruiting now

  • CHU Strasbourg-Hautepierre-Medecine Interne, Endocrinologie et Nutrition ( Site 0402)

    Strasbourg, Alsace, France 67098

    Recruiting now

  • Hôpital Edouard Herriot-oncologie ( Site 0405)

    Lyon, Auvergne-Rhône-Alpes, France 69003

    Recruiting now

  • Institut Paoli-Calmettes-Oncology ( Site 0406)

    Marseille, Bouches-du-Rhone, France 13009

    Active, not recruiting

  • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0407)

    Le Kremlin-Bicêtre, Paris, France 94270

    Recruiting now

  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0404)

    Paris, France 75014

    Recruiting now

  • Gustave Roussy ( Site 0403)

    Villejuif, Île-de-France Region, France 94805

    Recruiting now

  • Universitaetsklinikum Freiburg ( Site 0504)

    Freiburg im Breisgau, Baden-Wurttemberg, Germany 79106

    Recruiting now

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Department of Internal Medicine IV, Division ( Site 0501)

    München, Bavaria, Germany 80336

    Completed

  • Comprehensive Cancer Center Mainfranken-Div. of Endocrinology and Diabetes ( Site 0500)

    Würzburg, Bavaria, Germany 97080

    Recruiting now

  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 0505)

    Düsseldorf, North Rhine-Westphalia, Germany 40225

    Recruiting now

  • Charité Universitaetsmedizin Berlin - Campus Mitte-Department of Endocrinology and Metabolism ( Site 0503)

    Berlin, Germany 10117

    Recruiting now

  • Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály ( Site 0600)

    Budapest, Hungary 1083

    Recruiting now

  • Sheba Medical Center-Institute of Endocrinology, Diabetes and Metabolism ( Site 1400)

    Ramat Gan, Israel 5262100

    Recruiting now

  • Sourasky Medical Center ( Site 1401)

    Tel Aviv, Israel 6423906

    Recruiting now

  • University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704)

    Naples, Campania, Italy 80100

    Completed

  • Fondazione IRCCS Istituto Nazionale dei Tumori-S.C. Oncologia Medica 2- Sarcomi ( Site 0709)

    Milan, Lombardy, Italy 20133

    Recruiting now

  • Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 0706)

    Siena, Tuscany, Italy 53100

    Recruiting now

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0708)

    Bologna, Italy 40138

    Recruiting now

  • Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 0701)

    Brescia, Italy 25123

    Recruiting now

  • Ospedale San Raffaele-Oncologia Medica ( Site 0705)

    Milan, Italy 20132

    Completed

  • Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroe ( Site 0700)

    Milan, Italy 20141

    Recruiting now

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 0703)

    Verona, Italy 37134

    Recruiting now

  • Hokkaido University Hospital ( Site 1800)

    Sapporo, Hokkaido, Japan 060-8648

    Active, not recruiting

  • Yokohama City University Hospital ( Site 1804)

    Yokohama, Kanagawa, Japan 236-0004

    Active, not recruiting

  • Kochi Medical School Hospital ( Site 1807)

    Nankoku, Kochi, Japan 783-8505

    Active, not recruiting

  • National Cancer Center Hospital ( Site 1802)

    Chuo-ku, Tokyo, Japan 104-0045

    Active, not recruiting

  • Kyoto University Hospital ( Site 1806)

    Kyoto, Japan 606-8507

    Active, not recruiting

  • Tokyo Women's Medical University Adachi Medical Center ( Site 1803)

    Tokyo, Japan 123-8558

    Active, not recruiting

  • Universitair Medisch Centrum Utrecht ( Site 1530)

    Utrecht, Netherlands 3584 CX

    Recruiting now

  • Oslo Universitetssykehus Radiumhospitalet ( Site 2400)

    Oslo, Norway 0424

    Recruiting now

  • START Lisbon - Hospital de Santa Maria ( Site 2601)

    Lisbon, Lisbon District, Portugal 1649-035

    Recruiting now

  • Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2600)

    Porto, Portugal 4200-072

    Recruiting now

  • GBUZ Republican Clinical Oncological Dispensary ( Site 0804)

    Ufa, Baskortostan, Respublika, Russia 450054

    Completed

  • Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov ( Site 0805)

    Saint Petersburg, Leningradskaya Oblast', Russia 190020

    Completed

  • Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 0803)

    Saint Petersburg, Leningradskaya Oblast', Russia 198255

    Recruiting now

  • Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 0801)

    Moscow, Moscow, Russia 115522

    Recruiting now

  • Endocrinology Research Center of Rosmedtechnologies-Surgery ( Site 0809)

    Moscow, Moscow, Russia 117036

    Completed

  • National Cancer Centre Singapore ( Site 1700)

    Singapore, Central Singapore, Singapore 168583

    Recruiting now

  • Seoul National University Hospital ( Site 2001)

    Jongno-gu, Seoul, South Korea 03080

    Recruiting now

  • Asan Medical Center ( Site 2000)

    Songpa-gu, Seoul, South Korea 05505

    Recruiting now

  • MD Anderson Cancer Center-Oncology ( Site 1102)

    Madrid, Madrid, Comunidad de, Spain 28033

    Completed

  • Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1103)

    Madrid, Madrid, Comunidad de, Spain 28041

    Recruiting now

  • Hospital Universitario Central de Asturias-Medical Oncology ( Site 1101)

    Oviedo, Principality of Asturias, Spain 33011

    Recruiting now

  • Hospital Universitari Vall d'Hebron ( Site 1100)

    Barcelona, Spain 08035

    Recruiting now

  • Skanes University Hospital Lund ( Site 1200)

    Lund, Skåne County, Sweden 221 85

    Recruiting now

  • Karolinska Universitetssjukhuset Solna ( Site 1202)

    Stockholm, Stockholm County, Sweden 171 76

    Completed

  • Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1201)

    Uppsala, Uppsala County, Sweden 751 85

    Recruiting now

  • Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 1204)

    Gothenburg, Västra Götaland County, Sweden 413 45

    Recruiting now

  • Baskent University Adana Training Hospital ( Site 0906)

    Yüreğir, Adana, Turkey (Türkiye) 01250

    Recruiting now

  • Ege University Medicine of Faculty ( Site 0900)

    Bornova, İzmir, Turkey (Türkiye) 35100

    Recruiting now

  • Hacettepe Universitesi-oncology hospital ( Site 0901)

    Ankara, Turkey (Türkiye) 06230

    Recruiting now

  • Ankara Bilkent Şehir Hastanesi. ( Site 0904)

    Ankara, Turkey (Türkiye) 06800

    Recruiting now

  • Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 0902)

    Istanbul, Turkey (Türkiye) 34668

    Completed

  • Addenbrooke's Hospital ( Site 1309)

    Cambridge, Cambridgeshire, United Kingdom CB2 2QQ

    Recruiting now

  • Royal Free Hospital ( Site 1302)

    London, England, United Kingdom NW3 2QG

    Active, not recruiting

  • The Beatson West of Scotland Cancer Centre ( Site 1308)

    Glasgow, Glasgow City, United Kingdom G12 0YN

    Recruiting now

  • Hammersmith Hospital-Medical Oncology ( Site 1304)

    London, London, City of, United Kingdom W12 OHS

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

The main inclusion criteria include but are not limited to the following:

* Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
* Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
* Cohort B1: VHL Disease-associated tumors:

  * Have a diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis
  * Must be ≥18 years of age
* Has a life expectancy of at least 3 months

The main exclusion criteria include but are not limited to the following:

* Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan
* History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
* Any of the following: A pulse oximeter reading \<92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
* Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure
* Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention

Updated 2026-06-08 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.